{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+%28TDF%29", "query": { "intervention": "Tenofovir (TDF)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 519, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+%28TDF%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-21T12:56:00.207Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01533259", "title": "Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "Stribild", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2012-01", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2015-01-26", "last_synced_at": "2026-09-21T12:56:00.207Z", "location_count": 9, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01533259" }, { "nct_id": "NCT03350672", "title": "Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hiv" ], "interventions": [ { "name": "FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Philadelphia Fight", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2017-11-16", "completion_date": "2018-05-01", "has_results": true, "last_update_posted_date": "2021-09-30", "last_synced_at": "2026-09-21T12:56:00.207Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03350672" }, { "nct_id": "NCT03197961", "title": "Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "HIV/AIDS", "Contraception" ], "interventions": [ { "name": "tenofovir/emtricitabine", "type": "COMBINATION_PRODUCT" }, { "name": "DMPA", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Sharon Achilles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 15, "start_date": "2017-11-17", "completion_date": "2020-12-01", "has_results": false, "last_update_posted_date": "2020-12-03", "last_synced_at": "2026-09-21T12:56:00.207Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03197961" }, { "nct_id": "NCT01495702", "title": "Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "NNRTI", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "Stribild", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 439, "start_date": "2011-12", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-01-07", "last_synced_at": "2026-09-21T12:56:00.207Z", "location_count": 39, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Hayward, California + 29 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01495702" }, { "nct_id": "NCT04925752", "title": "Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pre-Exposure Prophylaxis of HIV Infection" ], "interventions": [ { "name": "Oral Lenacapavir (LEN)", "type": "DRUG" }, { "name": "F/TDF", "type": "DRUG" }, { "name": "Sub-cutaneous (SC) Lenacapavir (LEN)", "type": "DRUG" }, { "name": "Placebo SC LEN", "type": "DRUG" }, { "name": "PTM F/TDF", "type": "DRUG" }, { "name": "PTM Oral LEN", "type": "DRUG" }, { "name": "F/TAF (for US participants only)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 3292, "start_date": "2021-06-28", "completion_date": "2028-08", "has_results": true, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-09-21T12:56:00.207Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04925752" }, { "nct_id": "NCT00110305", "title": "A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus Type 1" ], "interventions": [ { "name": "TMC278 25 mg", "type": "DRUG" }, { "name": "TMC278 75 mg", "type": "DRUG" }, { "name": "TMC278 150 mg", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Non-nucleoside reverse transcriptase inhibitor (NRTIs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 368, "start_date": "2005-06", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2014-06-25", "last_synced_at": "2026-09-21T12:56:00.207Z", "location_count": 9, "location_summary": "Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110305" }, { "nct_id": "NCT05353283", "title": "PrEP Point-of-Care Brief-Intervention for Adherence Among Young Men Who Have Sex With Men", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Risk Reduction" ], "interventions": [ { "name": "Motivational Interviewing Counselling", "type": "BEHAVIORAL" }, { "name": "Point-of-care Urine Tenofovir Measurement", "type": "DEVICE" } ], "intervention_types": [ "BEHAVIORAL", "DEVICE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "30 Years", "sex": "MALE", "summary": "18 Years to 30 Years · Male only" }, "enrollment_count": 63, "start_date": "2023-09-01", "completion_date": "2025-07-01", "has_results": true, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-21T12:56:00.207Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05353283" }, { "nct_id": "NCT03270969", "title": "A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Prevention" ], "interventions": [ { "name": "Tenofovir Disoproxil Fumarate/Emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 15, "start_date": "2018-01-05", "completion_date": "2018-09-10", "has_results": false, "last_update_posted_date": "2023-09-15", "last_synced_at": "2026-09-21T12:56:00.207Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03270969" }, { "nct_id": "NCT07266831", "title": "A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Human Immunodeficiency Virus Type 1 (HIV-1) Infection" ], "interventions": [ { "name": "ISL", "type": "DRUG" }, { "name": "ULO", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo for BIC/FTC/TAF", "type": "DRUG" }, { "name": "Placebo to ISL/ULO", "type": "DRUG" }, { "name": "ISL/ULO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 570, "start_date": "2025-12-18", "completion_date": "2031-12-18", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-09-21T12:56:00.207Z", "location_count": 24, "location_summary": "Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Miami Gardens", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07266831" }, { "nct_id": "NCT01943799", "title": "Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic HBV Infection" ], "interventions": [ { "name": "GS-4774", "type": "BIOLOGICAL" }, { "name": "OAV Regimen", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 178, "start_date": "2013-09-13", "completion_date": "2015-03-03", "has_results": true, "last_update_posted_date": "2019-11-01", "last_synced_at": "2026-09-21T12:56:00.207Z", "location_count": 16, "location_summary": "Los Angeles, California • Pasadena, California • Sacramento, California + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01943799" } ] }